CLAIMS

1. A phospholipidic preparation consisting in a release system and a lexitropsin of general formula **I**



I (n=0,1)

in which R_1 is a functional group, preferably a basic one such as a simple or substituted amidine, a secondary or tertiary amine, a quaternary ammonium group, a simple or substituted guanidine, selected from :

-C(NH)NH_2, -C(NH)NHR_3, -NH_2, NHR_3 -$N(R_3)_2$, -NR_3R_4, -NH-C(NH)NH_2, -NH-C(NH)NHR_3, -$N(CH_2)_4$, -$N(R_3)_3$+

whereas R_2 represents an aliphatic, aromatic, or arylaliphatic acylic group, also if substituted with atomic groups containing one or more heteroatoms such as atoms of oxygen, nitrogen, or R_2 represents a sequence of one or more residues of 1-methyl-4-aminopyrrole-2-carboxylic acid, acylated or not acylated at the N-terminus, also terminating with a residue of 1-methyl-4-carboxamidopyrrole-2-carboxylic acid or with a residue of analogue aminoacids derived from an heterocycle different from pyrrole selected from furane, imidazole, thiophene, thiazole, or derived from benzene, pyridine, a diazine, pyrimidine, substituted or not at the terminal amino group with an acylic group, or containing, in place of the free or substituted amino group a

carboxamido group, and R_3 or R_4 are equal or different lower alkyl groups C_1 to C_4,

the release system being a liposome, a micelle, a nanoparticle, a phospholipidic complex or a supramolecular phospholipidic structure able to incorporate a compound of general structure I in stable and reversible form.

2. A preparation according to claim 1, in form of multilamellar liposomes, composed of phosphatidyl glycerol (PG), phosphatidyl choline (PC) and cholesterol (C) containing an entrapped lexitropsin of formula I in an amount comprised in the range 1-10 percent of the mass of the liposome.

3. A preparation according to claim 1, in form of phospholipidic vescicles composed by polyethyleneglycol ethanolamine(PEGPE), PG and partially hydrogenated egg phosphatidyl choline (PHEPC) containing 1-10 % by weight of a lexitropsin.

4. A preparation according to any one of claims 1-3, comprising distamycin (II) in the form of an organic or inorganic salt, preferably as the hydrochloride, as the active ingredient.



II

5. A preparation, according to any one of claims 1-3 comprising a compound X in the form of an organic or inorganic salt, preferably as the hydrochloride.



X

6. A topical preparation according to any one of claims 1-5, containing from 0.1 to 10% of active principle.

7. An injectable preparation according to any one of claims 1-5 providing a dosage from 0.1 to 20 mg of a lexitropsin of general formula I, II or X per kg body weight.

8. The use of the preparations of claims 1-7 for the preparation of medicaments for the treatment of viral, or bacterial, or protozoarian infections.